Jagson Pal Pharmaceuticals Limited.

BSE: 507789 NSE: JAGSNPHARM
Jagson Pal Pharmaceuticals Limited. - pharma in New Delhi, Delhi, India. FY 2026 financials and compliance.
CIN L74899DL1978PLC009181 Incorporated 17 August 1978 ROC Delhi HQ New Delhi, Delhi, India
Active Listed - NSE: JAGSNPHARM · BSE: 507789 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹287.23 Cr
▲ 6.89% YoY
EBITDA · FY 2026
₹70.07 Cr
▲ 18.24% YoY
Net profit · FY 2026
₹43.08 Cr
▼ 22.18% YoY
Authorised capital
₹25 Cr
Registered with MCA
Paid-up capital
₹13.36 Cr
Issued & subscribed
Open charges
None
Satisfied ₹80.8 Cr
Company age
48 yrs
Est. 1978
Employees · EPFO
1,308
Latest available

About Jagson Pal Pharmaceuticals Limited.

Data last updated: 04 January 2026

Jagson Pal Pharmaceuticals Limited. is a public limited company based in New Delhi, Delhi, India, a subsidiary of Aresko Progressive Private Limited. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 17 August 1978, the company has been in operation for over 48 years.

Registered with ROC Delhi under CIN L74899DL1978PLC009181. Listed on BSE: 507789 and NSE: JAGSNPHARM.

Capital: an authorised share capital of ₹25 Cr and a paid-up capital of ₹13.36 Cr. Formerly known as Jagson Pal Pharmaceuticals Private Limited. It is led by directors including Pallavi Dinodia Gupta and Radhika Carlton Pereira.

Last AGM: 24 September 2025. Financial statements filed for year ended 31 March 2025. Office: Innov8 3Rd Floor Plot No. 211, Okhla Phase – 3 New Delhi, Delhi, India – 110020.

As per the financials filed for FY 2025, the company reported a revenue of ₹276.91 Cr, a growth of 27% compared to the previous year.

The company has a workforce of approximately 1,308 employees as per the latest available data. It operates as a subsidiary of Aresko Progressive Private Limited.

The company is associated with 1 brand - Jagsonpal. As per MCA filings, the company has satisfied charges of ₹80.8 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website jagsonpal.com.

Company Details of Jagson Pal Pharmaceuticals Limited.
CIN L74899DL1978PLC009181
Registration Number 009181
Incorporation Date 17 August 1978
ROC Delhi
Listing Status Listed (BSE: 507789, NSE: JAGSNPHARM)
Company Status Active
Date of Last AGM 24 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Aresko Progressive Private Limited
Compliance Status Active Compliant
Key People
Manish Gupta Managing Director Pallavi Dinodia Gupta Director Radhika Carlton Pereira Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    jagsonpal.com
  • Social Media
  • Registered Address
    Innov8 3Rd Floor Plot No. 211, Okhla Phase – 3 New Delhi, Delhi, India – 110020
  • Industry
    Pharma, API Manufacturers
Company report
Jagson Pal Pharmaceuticals Limited. - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Jagson Pal Pharmaceuticals Limited. report

Financials, compliance, directors, charges, ownership and filings for Jagson Pal Pharmaceuticals Limited. in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Jagson Pal Pharmaceuticals Limited.

Jagson Pal Pharmaceuticals Limited. has one previous CIN (Corporate Identification Number): U74899DL1978PLC009181. The current CIN is L74899DL1978PLC009181, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L74899DL1978PLC009181 Current
U74899DL1978PLC009181 Previous

Associated Brands with Jagson Pal Pharmaceuticals Limited.

Jagson Pal Pharmaceuticals Limited. operates one associated brand: Jagsonpal. These brands represent Jagson Pal Pharmaceuticals Limited.'s diversified market presence and brand portfolio.

Brand Description Website
Jagsonpal
Traditional company manufacturing bulk drugs and finished formulations jagsonpal.com

Competitors & Alternatives of Jagson Pal Pharmaceuticals Limited.

Brands and companies operating in the same space as Jagson Pal Pharmaceuticals Limited. include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 7 more.

Competitor Description Location Founded
Concord Biotech Concord Biotech APIs and enzymes are manufactured through fermentation by the CDMO. Ahmedabad, India, India 2000
BDR Pharmaceuticals Internationals BDR Pharmaceuticals Internationals APIs and finished products are developed and manufactured. Mumbai, India, India 2003
Almac Group Almac Group Integrated CDMO services for biopharma R&D and manufacturing are offered. Craigavon, United Kingdom, United Kingdom 2001
Indoco Remedies Indoco Remedies APIs manufacturing and formulation services are provided in therapeutic segments. Mumbai, India, India 1947
Pharmaceutics International Pharmaceutics International Pharmaceutical dosage forms are manufactured by this CDMO. Hunt Valley, United States, United States 1994
Aurobindo Pharma Aurobindo Pharma Generic biocatalytic solutions are provided for pharmaceutical applications. Hyderabad, India, India 1986
Seqens Seqens Contract manufacturing services for small molecules and peptides are provided. Ecully, France, France 2003
Asymchem Asymchem APIs and peptides are developed and manufactured by Asymchem. Morrisville, United States, United States 1995
Aptuit Aptuit Contract research and development services for small molecules are offered. Greenwich, United States, United States 2004
Continuus Pharma Continuus Pharma MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development Woburn, United States, United States 2012

Business Activity of Jagson Pal Pharmaceuticals Limited.

Jagson Pal Pharmaceuticals Limited. is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Jagson Pal Pharmaceuticals Limited.

Jagson Pal Pharmaceuticals Limited. is audited by M/s Walker Chandiok & Co LLP, Chartered Accountants (ICAI peer reviewed, certificate valid till 2028-05-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
M/s Walker Chandiok & Co LLP, Chartered Accountants (ICAI peer reviewed, certificate valid till 2028-05-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Jagson Pal Pharmaceuticals Limited.

Jagson Pal Pharmaceuticals Limited. is currently managed by 8 directors, with 20 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Pallavi Dinodia Gupta
Also directs: S R Dinodia & Co Llp, Lumax Industries Limited, Indiamart Intermesh Limited and 2 more
Director 29 Jun 2022 4 Years 0 Months Current
Radhika Carlton Pereira
Also directs: Bajel Projects Limited, Camlin Fine Sciences Limited, Tips Films Limited and 1 more
Director 29 Jun 2022 4 Years 0 Months Current
Debasis Bikash Nandy
Also directs: Traveljunkie Solutions Private Limited, Tc Tours Limited, Sotc Travel Limited and 3 more
Director 29 Jun 2022 4 Years 0 Months Current
Prithipal Singh Kochhar
Also directs: Aresko Global Llp, I.K. Enterprises Private Limited, Suvinys Developers Private Limited and 5 more
Nominee Director 29 Jun 2022 4 Years 0 Months Current
Harsha Raghavan
Also directs: Camlin Fine Sciences Limited, Convergent Finance Llp, Sundrop Brands Limited and 5 more
Nominee Director 29 Jun 2022 4 Years 0 Months Current
Manish Gupta
Also directs: Solara Active Pharma Sciences Limited, Synthix Global Pharma Solutions Limited, Intron Life Sciences Private Limited
Managing Director 16 Jul 2022 3 Years 11 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Jagson Pal Pharmaceuticals Limited. FY 2026 filings available

Jagson Pal Pharmaceuticals Limited. reported revenue of ₹287.23 Cr (up 6.89% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹287.23 Cr ▲ 6.89%
Profit · FY 2026
₹43.08 Cr ▼ 22.18%
EBITDA · FY 2026
₹70.07 Cr ▲ 18.24%
Revenue₹ Cr · Standalone0100200300FY 2020: ₹159 Cr159FY 2020FY 2021: ₹188 Cr · +18.5% YoY188+18.5%FY 2021FY 2022: ₹226 Cr · +20.3% YoY226+20.3%FY 2022FY 2023: ₹237 Cr · +4.7% YoY237+4.7%FY 2023FY 2024: ₹209 Cr · -11.8% YoY209-11.8%FY 2024FY 2025: ₹269 Cr · +28.8% YoY269+28.8%FY 2025FY 2026: ₹287 Cr · +6.9% YoY287+6.9%FY 2026
Net Profit₹ Cr · Standalone0204060FY 2020: ₹8 Cr7.9FY 2020FY 2021: ₹17 Cr · +116.7% YoY17.1+116.7%FY 2021FY 2022: ₹20 Cr · +14.8% YoY19.6+14.8%FY 2022FY 2023: ₹27 Cr · +36.4% YoY26.7+36.4%FY 2023FY 2024: ₹22 Cr · -15.9% YoY22.5-15.9%FY 2024FY 2025: ₹55 Cr · +146.5% YoY55.4+146.5%FY 2025FY 2026: ₹43 Cr · -22.2% YoY43.1-22.2%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year050100Q1'25: ₹61 Cr · +10.8% YoY61.4+10.8%Q1'25Q2'25: ₹75 Cr · +24.2% YoY74.7+24.2%Q2'25Q3'25: ₹74 Cr · +56.7% YoY74+56.7%Q3'25Q4'25: ₹59 Cr · +34.7% YoY58.6+34.7%Q4'25Q1'26: ₹76 Cr · +23.1% YoY75.6+23.1%Q1'26Q2'26: ₹74 Cr · -0.3% YoY74.5-0.3%Q2'26Q3'26: ₹73 Cr · -1.5% YoY72.9-1.5%Q3'26Q4'26: ₹64 Cr · +9.6% YoY64.2+9.6%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹287.23 Cr ₹268.72 Cr ₹208.7 Cr ₹236.71 Cr ₹226.1 Cr ₹187.95 Cr ₹158.57 Cr
Other Income ₹12 Cr ₹8.19 Cr ₹9.28 Cr ₹5.73 Cr ₹3.34 Cr ₹4.39 Cr ₹2.53 Cr
Total Income ₹299.22 Cr ₹276.91 Cr ₹217.98 Cr ₹242.45 Cr ₹229.43 Cr ₹192.34 Cr ₹161.09 Cr
Cost of Materials Consumed ₹16.11 Cr ₹18.34 Cr ₹22.1 Cr ₹31.21 Cr ₹40.42 Cr ₹38.63 Cr ₹36.78 Cr
Purchases of Stock-in-Trade ₹89.19 Cr ₹80.22 Cr ₹53.98 Cr ₹57.59 Cr ₹49.75 Cr ₹36.86 Cr ₹18.15 Cr
Changes in Inventories -₹92.6 Lakh -₹2.13 Cr ₹3.9 Cr ₹4.3 Cr ₹5.61 Cr ₹5.28 Cr ₹1.25 Cr
Employee Benefit Expense ₹70.74 Cr ₹70.93 Cr ₹48.49 Cr ₹56.41 Cr ₹57.68 Cr ₹53.98 Cr ₹50.37 Cr
Finance Costs ₹1.03 Cr ₹95.8 Lakh ₹81.4 Lakh ₹41.27 Lakh ₹28.51 Lakh ₹51.35 Lakh ₹51.41 Lakh
Depreciation & Amortisation ₹9.44 Cr ₹8.13 Cr ₹1.66 Cr ₹1.21 Cr ₹1.53 Cr ₹1.09 Cr ₹1.13 Cr
Other Expenses ₹54.04 Cr ₹50.27 Cr ₹57.17 Cr ₹53.04 Cr ₹46.84 Cr ₹34.11 Cr ₹43.47 Cr
Total Expenses ₹239.62 Cr ₹226.73 Cr ₹188.11 Cr ₹204.18 Cr ₹202.11 Cr ₹170.47 Cr ₹151.68 Cr
Profit Before Exceptional Items & Tax ₹59.6 Cr ₹50.17 Cr ₹29.87 Cr ₹38.27 Cr ₹27.32 Cr ₹21.87 Cr ₹9.41 Cr
Exceptional Items -₹2.08 Cr ₹19.69 Cr ₹0 -₹3.46 Cr ₹0 ₹0 ₹0
Profit Before Tax ₹57.52 Cr ₹69.86 Cr ₹29.87 Cr ₹34.81 Cr ₹27.32 Cr ₹21.87 Cr ₹9.41 Cr
Total Tax Expense ₹14.44 Cr ₹14.5 Cr ₹7.41 Cr ₹8.09 Cr ₹7.73 Cr ₹4.81 Cr ₹1.54 Cr
Net Profit ₹43.08 Cr ₹55.36 Cr ₹22.46 Cr ₹26.72 Cr ₹19.59 Cr ₹17.06 Cr ₹7.87 Cr
Other Comprehensive Income ₹36.4 Lakh ₹21.9 Lakh ₹20.3 Lakh -₹9.36 Cr ₹1.36 Cr ₹15.16 Lakh ₹0
Total Comprehensive Income ₹43.45 Cr ₹55.58 Cr ₹22.67 Cr ₹17.37 Cr ₹20.95 Cr ₹17.21 Cr ₹7.87 Cr
EBITDA (computed) ₹70.07 Cr ₹59.26 Cr ₹32.35 Cr ₹39.89 Cr ₹29.13 Cr ₹23.47 Cr ₹11.06 Cr
Basic EPS ₹6.40 ₹8.26 ₹8.49 ₹10.20 ₹7.48 ₹6.51 ₹3.00
Diluted EPS ₹6.31 ₹8.22 ₹8.46 ₹10.20 ₹7.48 ₹6.51 ₹3.00
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹316.68 Cr ₹278.26 Cr ₹217.08 Cr ₹194.95 Cr
Non-current Assets ₹173.59 Cr ₹117.07 Cr ₹17.82 Cr ₹30.39 Cr
Current Assets ₹143.09 Cr ₹161.19 Cr ₹199.25 Cr ₹164.56 Cr
Property, Plant & Equipment ₹57.4 Lakh ₹61.1 Lakh ₹91 Lakh ₹18.35 Cr
Inventories ₹14.64 Cr ₹15.2 Cr ₹15 Cr ₹20.68 Cr
Trade Receivables ₹17.19 Cr ₹13.18 Cr ₹10.95 Cr ₹20.87 Cr
Cash & Equivalents ₹10.04 Cr ₹11.22 Cr ₹12.76 Cr ₹11.05 Cr
Equity (Net Worth) ₹276.17 Cr ₹239.95 Cr ₹187.4 Cr ₹158.89 Cr
Equity Share Capital ₹13.39 Cr ₹13.28 Cr ₹13.22 Cr ₹13.1 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹0 ₹0 ₹0
Total Debt (computed) ₹0 ₹0 ₹0 ₹0
Current Liabilities ₹28.3 Cr ₹25.9 Cr ₹19.13 Cr ₹27.57 Cr
Total Liabilities ₹40.51 Cr ₹38.31 Cr ₹29.68 Cr ₹36.06 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹46.81 Cr ₹55.3 Cr ₹35.17 Cr ₹40.15 Cr ₹5.6 Cr
Investing Cash Flow -₹35.65 Cr -₹45.15 Cr -₹24.55 Cr -₹51.62 Cr -₹26.21 Cr
Financing Cash Flow -₹12.15 Cr -₹11.7 Cr -₹8.91 Cr ₹0 -₹12.3 Cr
Capital Expenditure ₹0 ₹34.8 Lakh ₹24.8 Lakh ₹31.76 Lakh ₹46.75 Lakh
Free Cash Flow (computed) ₹46.81 Cr ₹54.95 Cr ₹34.92 Cr ₹39.83 Cr ₹5.13 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹10.48 Cr
Net Change in Cash -₹98.6 Lakh -₹1.55 Cr ₹1.71 Cr -₹11.47 Cr -₹32.91 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q1 FY24 Q4 FY23
Revenue from Operations ₹64.2 Cr ₹72.95 Cr ₹74.47 Cr ₹75.61 Cr ₹58.56 Cr ₹74.03 Cr ₹74.69 Cr ₹61.44 Cr ₹43.49 Cr ₹47.23 Cr ₹60.15 Cr ₹55.45 Cr
Other Income ₹3.17 Cr ₹2.98 Cr ₹3.03 Cr ₹2.83 Cr ₹2.77 Cr ₹2.32 Cr ₹1.65 Cr ₹1.44 Cr ₹2.49 Cr ₹2.52 Cr ₹2 Cr ₹2.56 Cr
Total Income ₹67.37 Cr ₹75.92 Cr ₹77.49 Cr ₹78.44 Cr ₹61.33 Cr ₹76.35 Cr ₹76.35 Cr ₹62.88 Cr ₹45.97 Cr ₹49.76 Cr ₹62.15 Cr ₹58.01 Cr
Cost of Materials Consumed ₹2.99 Cr ₹3.95 Cr ₹3.84 Cr ₹5.33 Cr ₹3.49 Cr ₹5.27 Cr ₹5.2 Cr ₹4.39 Cr ₹3.79 Cr ₹5.88 Cr ₹7.53 Cr ₹6.32 Cr
Purchases of Stock-in-Trade ₹19.89 Cr ₹22.81 Cr ₹23.8 Cr ₹22.69 Cr ₹17.5 Cr ₹21.12 Cr ₹22.03 Cr ₹20.03 Cr ₹12.06 Cr ₹14.15 Cr ₹13.59 Cr ₹17.8 Cr
Changes in Inventories ₹89.2 Lakh -₹31.1 Lakh -₹41.3 Lakh -₹1.09 Cr ₹73.8 Lakh ₹12.5 Lakh -₹87.2 Lakh -₹2.12 Cr ₹1.81 Cr -₹29.2 Lakh ₹1.17 Cr -₹1.62 Cr
Employee Benefit Expense ₹15.55 Cr ₹17.58 Cr ₹18.18 Cr ₹19.44 Cr ₹16.57 Cr ₹18.08 Cr ₹16.68 Cr ₹14.74 Cr ₹11.45 Cr ₹11.64 Cr ₹13.7 Cr ₹13.21 Cr
Finance Costs ₹25.2 Lakh ₹25.7 Lakh ₹26.5 Lakh ₹25.4 Lakh ₹25.9 Lakh ₹25.5 Lakh ₹22.9 Lakh ₹21.5 Lakh ₹21.7 Lakh ₹22.6 Lakh ₹15 Lakh ₹19.59 Lakh
Depreciation & Amortisation ₹2.32 Cr ₹2.39 Cr ₹2.39 Cr ₹2.35 Cr ₹2.31 Cr ₹2.41 Cr ₹2.34 Cr ₹1.07 Cr ₹40.3 Lakh ₹41.2 Lakh ₹39.3 Lakh ₹47.88 Lakh
Other Expenses ₹13.73 Cr ₹12.65 Cr ₹12.63 Cr ₹15.03 Cr ₹11.56 Cr ₹13.59 Cr ₹15.37 Cr ₹14.16 Cr ₹11.71 Cr ₹12.46 Cr ₹15.53 Cr ₹14.3 Cr
Total Expenses ₹55.62 Cr ₹59.32 Cr ₹60.68 Cr ₹64.01 Cr ₹52.41 Cr ₹60.86 Cr ₹60.98 Cr ₹52.49 Cr ₹41.44 Cr ₹44.48 Cr ₹52.06 Cr ₹50.69 Cr
Profit Before Exceptional Items & Tax ₹11.76 Cr ₹16.6 Cr ₹16.81 Cr ₹14.43 Cr ₹8.92 Cr ₹15.49 Cr ₹15.37 Cr ₹10.4 Cr ₹4.54 Cr ₹5.28 Cr ₹10.09 Cr ₹7.32 Cr
Exceptional Items ₹0 -₹2.08 Cr ₹0 ₹0 -₹21.2 Lakh ₹23.18 Cr ₹0 -₹3.29 Cr ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹11.76 Cr ₹14.52 Cr ₹16.81 Cr ₹14.43 Cr ₹8.71 Cr ₹38.67 Cr ₹15.37 Cr ₹7.11 Cr ₹4.54 Cr ₹5.28 Cr ₹10.09 Cr ₹7.32 Cr
Total Tax Expense ₹2.99 Cr ₹3.57 Cr ₹4.24 Cr ₹3.64 Cr ₹2.13 Cr ₹6.68 Cr ₹3.91 Cr ₹1.78 Cr ₹98.7 Lakh ₹1.32 Cr ₹2.61 Cr ₹1.72 Cr
Net Profit ₹8.76 Cr ₹10.95 Cr ₹12.57 Cr ₹10.8 Cr ₹6.58 Cr ₹31.99 Cr ₹11.46 Cr ₹5.33 Cr ₹3.55 Cr ₹3.96 Cr ₹7.48 Cr ₹5.6 Cr
Other Comprehensive Income ₹11 Lakh ₹2.7 Lakh ₹17 Lakh ₹5.7 Lakh -₹29 Lakh ₹6.3 Lakh ₹49.4 Lakh -₹4.8 Lakh -₹18.8 Lakh ₹11.2 Lakh -₹1.9 Lakh -₹6.05 Lakh
Total Comprehensive Income ₹8.87 Cr ₹10.98 Cr ₹12.74 Cr ₹10.85 Cr ₹6.29 Cr ₹32.05 Cr ₹11.95 Cr ₹5.28 Cr ₹3.36 Cr ₹4.08 Cr ₹7.46 Cr ₹5.54 Cr
EBITDA (computed) ₹14.33 Cr ₹19.24 Cr ₹19.46 Cr ₹17.04 Cr ₹11.48 Cr ₹18.16 Cr ₹17.94 Cr ₹11.68 Cr ₹5.16 Cr ₹5.92 Cr ₹10.63 Cr ₹8 Cr
Basic EPS ₹1.25 ₹1.67 ₹1.88 ₹1.60 ₹0.98 ₹4.74 ₹4.29 ₹1.94 ₹1.31 ₹1.48 ₹2.85 ₹2.14
Diluted EPS ₹1.21 ₹1.65 ₹1.87 ₹1.58 ₹0.98 ₹4.74 ₹4.25 ₹1.93 ₹1.31 ₹1.47 ₹2.85 ₹2.14
Latest 12 quarters shown of 24 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Jagson Pal Pharmaceuticals Limited.. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Jagson Pal Pharmaceuticals Limited.

As per the shareholding pattern filed with NSE for the quarter ended Jun 2026, promoters hold 69.36%, foreign institutional investors hold 2.46%, domestic institutional investors hold 0.31%, retail and other public shareholders hold 27.87% of Jagson Pal Pharmaceuticals Limited.. The company had 24,826 shareholders on record.

Promoters: 69.36%DII (Domestic Institutional): 0.31%FII (Foreign Institutional): 2.46%Retail & Others: 27.87%
Jun 2026
QUARTER
69.36% Promoters
0.31% DII (Domestic Institutional)
2.46% FII (Foreign Institutional)
27.87% Retail & Others
Promoter holding - history
Now 69.36% · Jun 2026High 70.34% · Sep 2019Low 67.39% · Dec 2025
66%67.5%69%70.5%72%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 69.17%Mar 2016: 69.17%Jun 2016: 69.17%Sep 2016: 69.17%Dec 2016: 69.17%Mar 2017: 69.17%Jun 2017: 69.17%Sep 2017: 69.17%Dec 2017: 69.17%Mar 2018: 69.17%Jun 2018: 69.17%Sep 2018: 69.51%Dec 2018: 70.12%Mar 2019: 70.26%Jun 2019: 70.33%Sep 2019: 70.34%Dec 2019: 70.34%Mar 2020: 70.34%Jun 2020: 70.34%Sep 2020: 70.34%Dec 2020: 70.34%Mar 2021: 70.34%Jun 2021: 70.34%Sep 2021: 70.34%Dec 2021: 70.34%Mar 2022: 68.71%Jun 2022: 68.71%Sep 2022: 68.71%Dec 2022: 68.71%Mar 2023: 68.71%Jun 2023: 68.71%Sep 2023: 68.71%Dec 2023: 68.48%Mar 2024: 68.09%Jun 2024: 68.04%Sep 2024: 67.97%Dec 2024: 67.81%Mar 2025: 67.78%Jun 2025: 67.65%Sep 2025: 67.54%Dec 2025: 67.39%Mar 2026: 67.89%Jun 2026: 69.36%70.34%67.39%69.36%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025
Promoters69.36%67.89%67.39%67.54%67.65%67.78%
Public30.64%32.11%32.61%32.46%32.35%32.22%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters67.89%67.78%68.09%68.71%68.71%70.34%70.34%70.26%69.17%69.17%69.17%
Public32.11%32.22%31.91%31.29%31.29%29.66%29.66%29.74%30.83%30.83%30.83%
Promoter change (YoY, %pts)+0.11-0.31-0.62+0.00-1.63+0.00+0.08+1.09+0.00+0.00-

Board & Governance of Jagson Pal Pharmaceuticals Limited.

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Jagson Pal Pharmaceuticals Limited. has 6 directors - 3 independent and 1 executive. The board is chaired by Harsha Raghavan.

DirectorPositionOn board sinceListed boards
Harsha Raghavan Non-Executive - Non Independent Director · Chairperson 2022-06-29 4
Manish Gupta Executive Director · MD 2022-07-16 2
Debasis Bikash Nandy Non-Executive - Independent Director 2022-06-29 1
Pallavi Dinodia Gupta Non-Executive - Independent Director 2022-06-29 4
Radhika Madhukar Dudhat Non-Executive - Independent Director 2022-06-29 4
Prithipal Singh Kochhar Non-Executive - Non Independent Director 2022-06-29 1
Board Committees
CommitteeMembers
Audit Committee Debasis Bikash Nandy (Chairperson), Harsha Raghavan, Pallavi Dinodia Gupta
Nomination and remuneration committee Radhika Madhukar Dudhat (Chairperson), Debasis Bikash Nandy, Prithipal Singh Kochhar
Stakeholders Relationship Committee Pallavi Dinodia Gupta (Chairperson), Debasis Bikash Nandy, Manish Gupta
Risk Management Committee Debasis Bikash Nandy (Chairperson), Harsha Raghavan, Radhika Madhukar Dudhat
Corporate Social Responsibility Committee Radhika Madhukar Dudhat (Chairperson), Pallavi Dinodia Gupta, Manish Gupta

Charges & Borrowings of Jagson Pal Pharmaceuticals Limited.

Open charges
₹0
Satisfied charges
₹80.8 Cr
Breakdown by lending institutions
Punjab & Sind Bank₹60.90 Cr
Others₹19.90 Cr
Latest charge details
DateLenderAmountStatus
26 Oct 2010 Punjab & Sind Bank ₹6.7 Cr Satisfied
26 Oct 2010 Punjab & Sind Bank ₹30 Lakh Satisfied
26 Oct 2010 Punjab & Sind Bank ₹31.9 Cr Satisfied
28 Jun 2006 Punjab & Sind Bank ₹22 Cr Satisfied
28 Jun 2006 Others ₹19.9 Cr Satisfied

Total charge records: 5 View all charges

Employees and EPFO Compliance at Jagson Pal Pharmaceuticals Limited.

Jagson Pal Pharmaceuticals Limited. has a workforce of 1,308 employees as of Feb 28, 2025.

Employee count
1,308
Active EPFO establishments
1
Employee growth
28.99%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Jagson Pal Pharmaceuticals Limited.

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Jagson Pal Pharmaceuticals Limited.

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Jagson Pal Pharmaceuticals Limited.

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Jagson Pal Pharmaceuticals Limited.

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Jagson Pal Pharmaceuticals Limited.

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Jagson Pal Pharmaceuticals Limited.

MSME Payment Delays by Jagson Pal Pharmaceuticals Limited.

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Jagson Pal Pharmaceuticals Limited.

Subsidiaries & Group Companies of Jagson Pal Pharmaceuticals Limited.

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Jagson Pal Pharmaceuticals Limited. with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Jagson Pal Pharmaceuticals Limited.

MCA Filings & Documents of Jagson Pal Pharmaceuticals Limited.

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Jagson Pal Pharmaceuticals Limited.

Directors
04 Nov 2025
Nirav Niranjankumar Vora was appointed as a Cfo on 04 Nov 2025 & has been associated with this company since 8 months 4 days.
Activity
24 Sep 2025
Jagson Pal Pharmaceuticals Limited. last Annual general meeting of members was held on 24 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Jagson Pal Pharmaceuticals Limited. has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi.
Directors
04 Apr 2023
Abhishek Joshi was appointed as a Company Secretary on 04 Apr 2023 & has been associated with this company since 3 years 3 months.
Directors
16 Jul 2022
Manish Gupta was appointed as a Managing Director on 16 Jul 2022 & has been associated with this company since 3 years 11 months.
Directors
29 Jun 2022
Pallavi Dinodia Gupta was appointed as a Director on 29 Jun 2022 & has been associated with this company since 4 years 10 days.

Recent News on Jagson Pal Pharmaceuticals Limited.

Frequently Asked Questions about Jagson Pal Pharmaceuticals Limited.

Jagson Pal Pharmaceuticals Limited. is an active public limited company in the pharma sector based in New Delhi, Delhi, India. It was incorporated on 17 August 1978 (48+ years old) and is registered under CIN L74899DL1978PLC009181. Listed on BSE: 507789 and NSE: JAGSNPHARM. The company has 1,308 employees.

Jagson Pal Pharmaceuticals Limited. reported revenue of ₹276.91 Cr for FY 2025 (up 27.00% YoY).

The current directors of Jagson Pal Pharmaceuticals Limited. are:

The primary industry of Jagson Pal Pharmaceuticals Limited. is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Jagson Pal Pharmaceuticals Limited. is listed on both BSE (code: 507789) and NSE (symbol: JAGSNPHARM).

Jagson Pal Pharmaceuticals Limited. can be reached at the registered office: Innov8 3Rd Floor Plot No. 211, Okhla Phase – 3 New Delhi, Delhi, India – 110020, or through the website jagsonpal.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available